Results 161 to 170 of about 10,171,198 (336)

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

8 Blood-fed females of Culex pipiens complex collected at Zoos in Metropolitan area(Contributed Papers,Proceedings of the 57th Annual Meeting of Eastern Region)

open access: bronze, 2006
Keiko Sawabe   +10 more
openalex   +2 more sources

Interpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 IWGT quantitative analysis expert working group meeting

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Quantitative risk assessments of chemicals are routinely performed using in vivo data from rodents; however, there is growing recognition that non‐animal approaches can be human‐relevant alternatives. There is an urgent need to build confidence in non‐animal alternatives given the international support to reduce the use of animals in toxicity ...
Marc A. Beal   +14 more
wiley   +1 more source

A high-resolution geospatial dataset of cyclist-involved crashes and segmented cycling infrastructure in the Guadalajara metropolitan area (2015-2024). [PDF]

open access: yesData Brief
Domínguez-Báez CA   +5 more
europepmc   +1 more source

Validation of self reported physical activity in adults of Pamplona Metropolitan Area (SPAIN) [PDF]

open access: bronze, 2014
Rosario Orzanco-Garralda   +2 more
openalex   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy